Pharmafile Logo

ivabradine

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Medscape Cardiology: Leading the Future of Heart Failure Education at HFSA 2025

Medscape Cardiology | theheart.org is proud to be at the forefront of the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), September 26–29, 2025, in Minneapolis, MN! With...

Medscape Education

- PMLiVE

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links